title: Pharmacokinetic model of iodine-131-G250 antibody in renal cell carcinoma patients.
abstract: A model that describes the pharmacokinetic distribution of 131I-labeled G250 antibody is developed.
  
  
  METHODS
  Previously collected pharmacokinetic data from a Phase I-II study of 131I-G250 murine antibody against renal cell carcinoma were used to develop a mathematical model describing antibody clearance from serum and the whole body. Survey meter measurements, obtained while the patient was under radiation precautions, and imaging data, obtained at later times, were combined to evaluate whole-body clearance kinetics over an extended period.
  
  
  RESULTS
  A linear two-compartment model was found to provide good fits to the data. The antibody was injected into Compartment 1, the initial distribution volume (Vd) of the antibody, which included serum. The antibody exchanged with the rest of the body, Compartment 2, and was eventually excreted. Data from 13 of the 16 patients fit the model with unique parameters; the maximum, median and minimum values for model-derived Vd were 6.3, 3.7 and 2.11, respectively. The maximum, median and minimum values for the excretion rate were 8 x 10(-2), 2.4 x 10(-2) and 1.3 x 10(-2) hr(-1), respectively. Parameter sensitivity analysis showed that a change in the transfer rate constant from serum to the rest of the body had the greatest effect on serum cumulative activity and that the rate constant for excretion had the greatest effect on whole-body cumulative activity.
  
  
  CONCLUSIONS
  A linear two-compartment model was adequate in describing the serum and whole-body kinetics of G250 antibody distribution. The median initial distribution volume predicted by the model was consistent with the nominal value of 3.81. A wide variability in fitted parameters was observed among patients, reflecting the differences in individual patient clearance and exchange kinetics of G250 antibody. By selecting median parameter values, such a model may be used to evaluate and design prolonged multiple administration radioimmunotherapy protocols.
authors.affiliation: Department of Medical Physics, Nuclear Medicine Service, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
authors.forename: A
authors.initials: A
authors.lastname: Loh
authors.forename: G
authors.initials: G
authors.lastname: Sgouros
authors.forename: J A
authors.initials: JA
authors.lastname: O'Donoghue
authors.forename: D
authors.initials: D
authors.lastname: Deland
authors.forename: D
authors.initials: D
authors.lastname: Puri
authors.forename: P
authors.initials: P
authors.lastname: Capitelli
authors.forename: J L
authors.initials: JL
authors.lastname: Humm
authors.forename: S M
authors.initials: SM
authors.lastname: Larson
authors.forename: L J
authors.initials: LJ
authors.lastname: Old
authors.forename: C R
authors.initials: CR
authors.lastname: Divgi
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000378:metabolism / Q000532:radiotherapy*; D005260:Female; D006801:Humans; D007457:Iodine Radioisotopes / Q000627:therapeutic use*; D007680:Kidney Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D008297:Male; D008875:Middle Aged; D008962:Models, Theoretical; D016499:Radioimmunotherapy; D014018:Tissue Distribution
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; C106533:G250 monoclonal antibody; D007457:Iodine Radioisotopes